14 Best Holding Company Stocks to Buy Right Now

Page 8 of 13

6. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders: 98

Johnson & Johnson (NYSE:JNJ) is a healthcare and pharmaceutical company committed to excelling in innovative medicine and MedTech. The company has been operational for more than 135 years and now boasts a family of 130,000 employees focused on serving people with complex diseases using innovative medicine and technology. Some of its key therapeutic areas include Oncology, Immunology, Neuroscience, Cardiopulmonary, and Specialty ophthalmology. Johnson & Johnson (NYSE:JNJ) also has stakes in several subsidiaries including Janssen Pharmaceuticals, Ethicon Inc., Abiomed, and Johnson & Johnson Vision, to name a few.

On February 3, Vamil Divan, an analyst at Guggenheim, raised his price target on JNJ from $162 to $166, keeping a neutral rating on the stock. The decision came after JNJ released earnings for the fourth quarter of 2024, largely meeting expectations. The analyst firm is particularly drawn to see how its pipeline and execution in oncology, neuroscience, and immunology play out. In addition to that, Divan is also looking forward to seeing how JNJ sustains its mid-single-digit growth expectations while dealing with immediate headwinds.

In the fiscal year 2024, Johnson & Johnson (NYSE:JNJ) generated $88.8 billion in revenue, up by 4.3%. Its Innovative Medicine Worldwide segment logged $57 billion and its World MedTech segment logged $31.9 billion in sales. According to the company, 2024 was quite a transformational year for JNJ, marking strong growth in its medicine portfolio and acceleration in innovative discoveries.

Page 8 of 13